Vogenx (VOGX) Stock Price, News & Analysis

Company Overview

Vogenx, Inc. was a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and autoimmune diseases. The company’s research centered on novel small-molecule therapies intended to modulate immune-system activity and reduce inflammation.

Vogenx’s lead investigational compound was VGX-1027, an orally administered anti-inflammatory agent studied for potential use in conditions including type 1 diabetes and other immune-mediated diseases. The company’s programs were primarily in the research and clinical-development stages, and its products were not broadly commercialized.

Vogenx was a U.S.-based biotechnology company. Publicly available information about its later operations, leadership, commercial activities and current corporate status is limited.

Key Stats

• Today's Range: $16.37 to $19.92
• 50-Day Range: N/A
• 52-Week Range: $12.95 to $38.41
• Volume: 60,907 shs
• Average Volume: 136,921 shs
• Market Capitalization: $254.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $48.50
• Consensus Rating: Buy

Vogenx Stock Analysis - MarketRank™

Vogenx scored higher than 67% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Vogenx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Vogenx has a consensus price target of $48.50, representing about 182.8% upside from its current price of $17.15.

Amount of Analyst Coverage

Vogenx has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Vogenx are expected to decrease in the coming year, from ($0.61) to ($1.52) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.17% of the float of Vogenx has been sold short.

Short Interest Ratio / Days to Cover

Vogenx has a short interest ratio ("days to cover") of 0.17, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vogenx has recently increased by 40.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vogenx does not currently pay a dividend.

Dividend Growth

Vogenx does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Vogenx has a news sentiment score of 2.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Vogenx this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 1 people have added Vogenx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vogenx insiders have not sold or bought any company stock.

Percentage Held by Institutions

Vogenx has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 9/17/2026
• Today: 10/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:VOGX
• CIK: 1903784
• Web: vogenx.com
• Phone: 919-659-5677
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Vogenx: $48.50
• High Price Target: $55.00
• Low Price Target: $42.00
• Potential Upside/Downside: +182.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.44
• Quick Ratio: 0.44

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 14,850,000
• Free Float: N/A
• Market Cap: $254.68 million
• Optionable: N/A
• Beta: N/A